InterPath001

Overview

InterPath001 is the Moderna/Merck melanoma phase 3 trial discussed in E250｜mRNA的第二战场：对话英博，拆解Moderna人类首个肿瘤疫苗三期突破.

Current Profile

The source describes InterPath001 as a global, multicenter, randomized, double-blind trial enrolling more than 1,000 postoperative later-stage melanoma patients. One arm receives an individualized mRNA tumor vaccine plus a PD-1 drug, and the comparison arm receives PD-1 treatment alone.

The episode treats the trial as important because the combination reached a statistically significant recurrence-free-survival result. The same source keeps the result preliminary: HR, subgroup results, full efficacy data, total-survival evidence, regulatory review, and cross-tumor implications remain unresolved.

Key Characteristics

• Phase 3 trial used as the episode’s key validation signal for individualized mRNA cancer vaccines.
• Focused on postoperative later-stage melanoma rather than healthy-person cancer prevention.
• Compares vaccine plus PD-1 therapy against PD-1 therapy alone.
• Uses recurrence-free survival as the reported primary endpoint in the source.
• Remains preliminary in the source because detailed HR, subgroup, approval, and survival data are not yet disclosed there.

Evidence

• Trial design: E250｜mRNA的第二战场：对话英博，拆解Moderna人类首个肿瘤疫苗三期突破 describes the study as global, multicenter, randomized, double-blind, and enrolling more than 1,000 patients.
• Patient and treatment setting: E250｜mRNA的第二战场：对话英博，拆解Moderna人类首个肿瘤疫苗三期突破 places the trial after melanoma surgery and compares individualized vaccine plus PD-1 against PD-1 alone.
• Endpoint boundary: E250｜mRNA的第二战场：对话英博，拆解Moderna人类首个肿瘤疫苗三期突破 says recurrence-free survival reached statistical significance, while HR and subgroup details were not disclosed in the episode.

Qualifications

This page is a source note-derived trial summary, not a clinical-trial registry entry, regulatory document, medical recommendation, or independent verification of trial results.

What Changed

• Created a source-scoped trial page to separate the InterPath001 endpoint and design claims from broader Moderna/Merck platform claims.

Relationships

• Moderna - company associated with the individualized mRNA vaccine branch in the source.
• Merck / 默沙东 - PD-1 and co-development partner context in the source.
• Individualized Cancer Vaccine - therapy being tested.
• Recurrence-Free Survival Endpoint - endpoint used to interpret the positive readout.
• Cancer Vaccine Platform - broader modality category.
• Clinical Development Capability - trial-design and evidence-building context.